Search

Meeting Coverage:

EURETINA Congress

EURETINA: 2018

Understanding the ALTAIR Study

Masahito Ohji, MD

Show Description +

Masahito Ohji, MD, details the structure and outcomes of the ALTAIR study, which examined two different treat-and-extend regimens with aflibercept (Eylea, Regeneron) in patients with wet AMD. Dr. Ohji provides data from the study's 96-week endpoint and discusses how the two study arms were (and were not) alike.

Posted: 9/22/2018

Keywords:

aflibercept

•

Age-Related Macular Degeneration (AMD)

•

Euretina Vienna

•

Wet AMD

Up Next

Three Exciting New Drugs

Three Exciting New Drugs

Pravin U. Dugel, MD

Value of Recent Surgical Innovations

Value of Recent Surgical Innovations

José García-Arumí, MD, PhD

The One Thing Every Doctor Can Do to Improve Efficiency in the Office

The One Thing Every Doctor Can Do to Improve Efficiency in the Office

Nadia K. Waheed, MD, MPH, Pravin U. Dugel, MD

Disrupted Imaging on OCTA

Disrupted Imaging on OCTA

Nadia K. Waheed, MD, MPH

Micropulse Laser in BRVO

Micropulse Laser in BRVO

Matteo Forlini, MD

Gene Therapy in Retinitis Pigmentosa

Gene Therapy in Retinitis Pigmentosa

Robert E. MacLaren, MB, ChB, DPhil, FRCOphth, FRCS, FACS, FMedSci

Can We Get Smaller Than 27-Gauge Instrumentation?

Can We Get Smaller Than 27-Gauge Instrumentation?

José García-Arumí, MD, PhD, Robert E. MacLaren, MB, ChB, DPhil, FRCOphth, FRCS, FACS, FMedSci

Can Technology Lead to a Seamless Diagnosis?

Can Technology Lead to a Seamless Diagnosis?

William Tucker, MD

Management of RVO

Management of RVO

Anat Loewenstein, MD

Trials on Steroids for Diabetic Eye Disease

Trials on Steroids for Diabetic Eye Disease

Albert J. Augustin, MD

Is There Any Hope for Dry AMD Patients?

Is There Any Hope for Dry AMD Patients?

Anat Loewenstein, MD, William Tucker, MD

Back to All Videos

Understanding the ALTAIR Study

Masahito Ohji, MD

Masahito Ohji, MD, details the structure and outcomes of the ALTAIR study, which examined two different treat-and-extend regimens with aflibercept (Eylea, Regeneron) in patients with wet AMD. Dr. Ohji provides data from the study's 96-week endpoint and discusses how the two study arms were (and were not) alike.

Posted: 9/22/2018

Keywords:

aflibercept

•

Age-Related Macular Degeneration (AMD)

•

Euretina Vienna

•

Wet AMD

Please log in to leave a comment.

More From EURETINA: 2018 Coverage

Three Exciting New Drugs

Three Exciting New Drugs

Pravin U. Dugel, MD

Value of Recent Surgical Innovations

Value of Recent Surgical Innovations

José García-Arumí, MD, PhD

The One Thing Every Doctor Can Do to Improve Efficiency in the Office

The One Thing Every Doctor Can Do to Improve Efficiency in the Office

Nadia K. Waheed, MD, MPH, Pravin U. Dugel, MD

Disrupted Imaging on OCTA

Disrupted Imaging on OCTA

Nadia K. Waheed, MD, MPH

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of EURETINA: 2018.